Thyroid hormone action in the heart

被引:505
作者
Kahaly, GJ
Dillmann, WH
机构
[1] Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA
[2] Gutenberg Univ Hosp, Dept Med 1, Endocrine Unit, D-55101 Mainz, Germany
关键词
D O I
10.1210/er.2003-0033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The heart is a major target organ for thyroid hormone action, and marked changes occur in cardiac function in patients with hypo- or hyperthyroidism. T-3-induced changes in cardiac function can result from direct or indirect T-3 effects. Direct effects result from T-3 action in the heart itself and are mediated by nuclear or extranuclear mechanisms. Extranuclear T-3 effects, which occur independent of nuclear T-3 receptor binding and increases in protein synthesis, influence primarily the transport of amino acids, sugars, and calcium across the cell membrane. Nuclear T-3 effects are mediated by the binding of T-3 to specific nuclear receptor proteins, which results in increased transcription of T-3-responsive cardiac genes. The T-3 receptor is a member of the ligand-activated transcription factor family and is encoded by cellular erythroblastosis A (c-erb A) genes. T-3 also leads to an increase in the speed of diastolic relaxation, which is caused by the more efficient pumping of the calcium ATPase of the sarcoplasmic reticulum. This T-3 effect results from T-3-induced increases in the level of the mRNA coding for the sarcoplasmic reticulum calcium ATPase protein, leading to an increased number of calcium ATPase pump units in the sarcoplasmic reticulum.
引用
收藏
页码:704 / 728
页数:25
相关论文
共 291 条
[1]   Thyroid hormone transporters: recent advances [J].
Abe, T ;
Suzuki, T ;
Unno, M ;
Tokui, T ;
Ito, S .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (05) :215-220
[2]  
AGNER T, 1984, DAN MED BULL, V31, P157
[3]   PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK [J].
ANDERSON, DC ;
ASINGER, RW ;
NEWBURG, SM ;
FARMER, CC ;
WANG, K ;
BUNDLIE, SR ;
KOLLER, RL ;
JAGIELLA, WM ;
KREHER, S ;
JORGENSEN, CR ;
SHARKEY, SW ;
FLAKER, GC ;
WEBEL, R ;
NOLTE, B ;
STEVENSON, P ;
BYER, J ;
WRIGHT, W ;
CHESEBRO, JH ;
WIEBERS, DO ;
HOLLAND, AE ;
MILLER, DM ;
BARDSLEY, WT ;
LITIN, SC ;
MEISSNER, I ;
ZERBE, DM ;
MCANULTY, JH ;
MARCHANT, C ;
COULL, BM ;
FELDMAN, G ;
HAYWARD, A ;
GANDARA, E ;
MACMILLAN, K ;
BLANK, N ;
LEONARD, AD ;
KANTER, MC ;
ISENSEE, LM ;
QUIROGA, ES ;
PRESTI, CH ;
TEGELER, CH ;
LOGAN, WR ;
HAMILTON, WP ;
GREEN, BJ ;
BACON, RS ;
REDD, RM ;
CADELL, DJ ;
GOMEZ, CR ;
JANOSIK, DL ;
LABOVITZ, AJ ;
KELLEY, RE ;
CHAHINE, R .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :1-5
[4]  
ANDERSON DC, 1992, ANN INTERN MED, V116, P6
[5]   EFFECT OF THYROID-HORMONE ON THE EXPRESSION OF MESSENGER-RNA ENCODING SARCOPLASMIC-RETICULUM PROTEINS [J].
ARAI, M ;
OTSU, K ;
MACLENNAN, DH ;
ALPERT, NR ;
PERIASAMY, M .
CIRCULATION RESEARCH, 1991, 69 (02) :266-276
[6]   Cardiac systolic and diastolic function at rest and exercise in subclinical hypothyroidism: Effect of thyroid hormone therapy [J].
Arem, R ;
Rokey, R ;
Kiefe, C ;
Escalante, DA ;
Rodriguez, A .
THYROID, 1996, 6 (05) :397-402
[7]   ATRIAL ELECTROPHYSIOLOGY IN EXPERIMENTAL HYPERTHYROIDISM IN RABBITS [J].
ARNSDORF, MF ;
CHILDERS, RW .
CIRCULATION RESEARCH, 1970, 26 (05) :575-&
[8]   THE HEART AND THYROID-DISEASE [J].
ARONOW, WS .
CLINICS IN GERIATRIC MEDICINE, 1995, 11 (02) :219-229
[9]   Subclinical hyperthyroidism as a risk factor for atrial fibrillation [J].
Auer, J ;
Scheibner, P ;
Mische, T ;
Langsteger, W ;
Eber, O ;
Eber, B .
AMERICAN HEART JOURNAL, 2001, 142 (05) :838-842
[10]  
Ba Von, 1840, WOCHENSCHR FAR GES H, V13, P197